Close

Enanta Pharma (ENTA) Reports Start of Phase 2b Trial with Regimen Containing HCV Protease Inhibitor ABT-493

September 10, 2014 10:26 AM EDT Send to a Friend
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login